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In heart transplantation CAV is the main cause for the late cardiac graft loss. 
The pathogenesis of CAV remains unclear and complex involving immune and 
non- immune factors. The rational of this study was to investigate explanted 
failing grafts in the light of new concepts in rejection mechanisms, namely AMR.
This retrospective multicentric study (Nantes, Paris- La Pitié, and Paris- 
HEGP) collected 31 explanted cardiac grafts failing 1 year posttransplan-
tation. The vasculature of the grafts was assessed from epicardial coronary 
arteries to myocardial microcirculation. The lesions were classi¿ ed as follows: 
- Classical coronary atherosclerosis exhibiting the features of natural coro-
nary artery atherosclerosis; - CAV with concentric intimal hyperplasia and 
media atrophy (arteriosclerosis); - Vascular inÀ ammation in the arteries cha-
racterized by endothelitis ± media in¿ ltration and in the microcirculation with 
intracapillary leukocyte stasis. Immunohistochemistry was performed to detect 
C4d complement fraction deposition and CD68- positive macrophages. The 
protocol endomyocardial biopsies performed before the graft removal were 
assessed again by 4 observers blind to the explanted graft pathology using 
histology and immunohistochemistry. Donor speci¿ c antibodies (DSA) were 
retrospectively assessed in stored sera using Luminex SA technique.
A pure classical coronary atherosclerosis pattern was observed in 6/31 
(19%). A pure pattern of CAV was present in 12/31 (39%) and a mixed 
pattern associating CAV and atherosclerosis features in 9/31 (29%). The coro-
nary arteries were devoid of signi¿ cant lesions in 4/31 (13%). Interestingly 
the CAV pure and mixed patterns were associated with vascular inÀ ammation 
within the arteries and/or the microcirculation with C4d deposits and macro-
phages (15/21) in the explanted grafts versus nil (0/6) in pure atherosclerosis 
pattern (p<0.002). Furthermore they were associated with previous AMR epi-
sodes on endomyocardial biopsies (11/21) as shown by intravascular macro-
phages and/or C4d deposits and by positive DSA (10/14) versus nil in pure 
atherosclerosis pattern (p<0.05 and p=0.05, respectively).
In failing cardiac grafts CAV lesions are associated with makers of AMR. 
CAV should be the consequence in coronary arteries of an ongoing AMR process.
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Dilated cardiomyopathy (DCM) associates left ventricular dilatation 
and systolic dysfunction. It is a major cause of heart failure and cardiac 
transplantation. LMNA is the most frequent gene implicated in DCM with 
conduction and/or rhythm defects. It encodes lamin A/C, nuclear envelope 
proteins. The pathomechanisms linking LMNA mutations to DCM remain 
to be elucidated. The aim of this study was to characterize the cardiac phe-
notype of mice carrying a Lmna mutation associated with severe phenotype 
in humans. The model was generated by deletion of 3 nucleotides encoding 
lysine 32 in Lmna (LmnaΔK32). Heart function was assessed by echocardio-
graphy and ECG in heterozygous (Het) and wild- type (WT) mice. Lamin 
A/C mRNA and protein levels were measured by qPCR and Western blot. 
Het mice did not show rhythm/conduction defect. They progressively deve-
loped cardiac dysfunction and DCM, and died between 35 and 70 weeks of 
age. Before the development of DCM, lamin A/C protein level was 50% 
lower, whereas Lmna mRNA level was similar in Het and WT mice, sug-
gesting degradation of ΔK32- lamin. We hypothesised it is degraded by the 
ubiquitin- proteasome system (UPS). We overexpressed Flag- tagged Wt or 
ΔK32- lamin A in neonatal cardiomyocytes and treated them with an UPS 
inhibitor. The treatment stabilized ΔK32- lamin, meaning UPS was indeed 
involved in its degradation. After development of DCM, lamin A/C level 
was similar in Het and WT hearts, evoking UPS impairment. Function of 
UPS was assessed in vivo by crossing Het and WT mice with UbG76V- GFP 
transgenic mice, expressing a UPS reporter substrate. Levels of UbG76V- GFP 
and ubiquitinated proteins were 2- fold higher in Het than in WT mice, sup-
porting a global impairment of UPS in the heart of Het mice. To conclude, 
Het LmnaΔK32 mice are the ¿ rst knock- in Lmna model with a cardiac- 
speci¿ c phenotype at the heterozygous state. Our data provide evidence of 
degradation of ΔK32- lamin by UPS, followed by its impairment with pro-
gression of DCM
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Loss- of- function mutations of SCN5A, the gene encoding Nav1.5 Na+ 
channel, are associated with progressive cardiac conduction defects (PCCD). 
To understand the pathophysiology of PCCD, we studied a Scn5a hetero-
zygous knockout (Scn5a+/- ) mouse model and showed that these mice develop 
extensive ¿ brosis during ageing. Fibrosis is due to accumulation of extracel-
lular matrix and absence of degradation. As cardiac ¿ broblasts are key players 
in ¿ brotic remodelling, we hypothesized that ¿ broblasts could express Nav1.5 
channel and that reduced expression of Nav1.5 in Scn5a+/-  mice could partly 
explain ageing- related development of ¿ brosis.
Nav1.5 expression was investigated in cultured cardiac ¿ broblasts at 4, 
6, 8 and 10 days after isolation from 10- week- old mice. Quantitative real- 
time RT- PCR experiment showed the presence of Nav1.5 mRNA in cardiac 
¿ broblasts from wild- type mice (n=3 cultures). Western- blotting and immu-
nocytochemistry experiments demonstrated that Nav1.5 channel is expressed 
in cardiac ¿ broblasts from wild- type (WT) mice and that this expression is 
reduced in cardiac ¿ broblasts from Scn5a+/-  mice (n=5). During WT ¿ bro-
blasts differentiation into myo¿ broblasts, the expression of Nav1.5 channel 
is decreased (n=5). This reduction of Nav1.5 expression is in relation with 
an increased expression of α- SMA (alpha- smooth muscle actin, n=5). We 
observed that RhoA GTPase (n=3) and SPARC (Secreted Protein Acidic and 
Rich in Cysteine, a regulator of collagen maturation) expression is increased 
in cardiac ¿ broblasts from Scn5a+/-  mice as compared to ¿ broblasts from WT 
mice (n=5). SPARC expression is also increased in whole ventricle prepara-
tions from 20- week- old Scn5a+/-  mice versus WT mice(n=5).
To conclude, Nav1.5 sodium channel is expressed in cardiac ¿ broblasts and 
seems to be involved in ¿ broblasts remodelling. We hypothesize that reduction 
of Nav1.5 expression in cardiac ¿ broblasts could ¿ ne tune pro- ¿ brotic remo-
delling in Scn5a+/-  mice.
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Objectives: Levosimendan is a positive inotropic drug developed for the 
treatment of acute de novo or decompensated heart failure, which acts via 
selective binding on cardiac troponin C, increasing the sensitivity of myo¿ -
laments to calcium and thus heart contraction. The aim of this study was to 
describe quantitatively by which internal routes Levosimendan exerts its ino-
tropic action [1]. 
Methodology: The inotropic effect of Levosimendan was analysed on 
Langendorff perfused guinea pig hearts using Modular Control and Regulation 
Analysis (MoCA), a non- invasive and integrative approach to study in situ 
control and regulation of cardiac energetics by 31P NMR measurement of 
energetic intermediates. Heart energetics is considered as a Supply/Demand 
system connected by the pool of energetic intermediates (PCr). 
Results: MoCA was applied in the present study to describe MoCA’s com-
plete description of the effect of Levosimendan is presented below. The ana-
lysis con¿ rmed that Levosimendan only activates the energy Demand module 
(+50.7%), with no effect on (+5.1%). The increase of contractile activity 
(+45%) is almost completely due to the Global effect on Demand (+44.5%), 
the necessary increase in energy Supply is the consequence of an Indirect 
Supply activation by PCr (+40%). 
Conclusion: MoCA demonstrated here that Levosimendan inotropic action 
on relies entirely on its calcium- sensitizing properties leading to myo¿ lament 
activation. Therefore, these results exclude any signi¿ cant intervention of a 
direct activation of the Supply module, either by cytosolic calcium increase or 
by phosphodiesterase 3 inhibition. 
This application of MoCA illustrates the possible use of this approach for 
the discrimination of physiologically relevant effects of a drug on heart.
1. Deschodt- Arsac, V., et al. Am J Physiol Regul Integr Comp Physiol, 
2010. 299(3): p. R786- 92.
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MoCA analysis of the effects of Levosimendan
0242
Peripartum cardiomyopathy: clinical presentation, diagnosis and prog-
nosis
Zied Frikha [Orateur] (1), Longo Salma (2), Ihsen Zairi (3), So¿ en 
Kammoun (4), Baha Alhabil (5), Farouk Jawedi (5), Sana Fennira (3), 
Sondos Kraim (6)
(1) Resident dans les hopitaux de tunis, cardiologie, Sfax, Tunisie - (2) pro-
fesseur, cardiologie, Marsa, Tunisie - (3) assistant, hôpital habib thameur, 
Tunis, Tunisie - (4) Hôpital Habib Thameur, service de cardiologie, Tunis, 
Tunisie - (5) Resident, Tunis, Tunisie - (6) Hôpital Habib Thameur, cardi-
ologie, Tunis, Tunisie
Background: Peripartum cardiomyopathy (PPCM) is a rare but serious 
form of cardiac failure affecting women in the last months of pregnancy or 
early puerperium. Its etiopathogenesis is still poorly understood. 
Purposes: The purpose of this work is to study the clinical presentation and 
diagnosis, as well as the prognosis of this pathology.
Methods: Retrospective study of 10 cases of peripartum cardiomyopathy 
admitted in the cardiology department between January, 1993 and January, 
2011.
Results: The mean age was 32 years old (range from 21 to 45 years). Three 
patients had gemellary pregnancies and four suffered toxemia. Congestive 
cardiac failure, mainly of the left ventricle, with acute pulmonary edema, was 
the main symptom. Thromboembolic complications were noted in 5 cases. Chest 
X- ray showed a cardiothoracic index above 0.6. Echocardiography showed a 
mean Left ventricular end diastolic diameter above 61.5+/- 1.8cm, a mean Left 
ventricular end systolic dimensions above 51.4+/- 2.65cm and a Left ventri-
cular ejection fractions of 29.8+/- 5.74%. Raised pulmonary arterial pressure 
was observed in 4 patients. Treatment included diuretics and converting enzyme 
inhibitor. Two patients required inotropic therapy. The total mortality was 20%. 
During 68±14 months of follow- up seven patients recovered totally and in one 
echocardiography showed a persisting impaired left ventricular function. 
Conclusion: Peripartum cardiomyopathy remains a life- threatening disease. 
Prognosis is highly related to reversal of ventricular dysfunction.
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Background:  Heart failure (HF) is associated with the desensitization of 
beta- adrenergic signaling transduction resulting in a decrease of cAMP bioa-
vailability, the critical regulator contractile function. Consistently, reversing 
or bypassing beta- adrenergic desensitization in animal models of HF led to 
symptomatic improvement; young mice (2- 4mo- old) over- expressing calcium/
calmodulin activated adenylyl cyclase type 8 (AC8TM) showed an improved 
beta- adrenergic reactivity which enhanced - cAMP synthesis, - PKA activity 
and - contractile function (Lipskaia et al., 2000). We now explore whether the 
bene¿ cial effect of adenylyl cyclase over- expression on cardiac function is 
modi¿ ed throughout aging. 
Methods and Results: Cardiac function of AC8TM was monitored from 2 
to 16 months of age by echocardiography. No difference in basal cardiac func-
tion was detected in young mice (2- 6 month old). Starting at 8 months, echo-
cardiography revealed a progressive increase in left ventricular size evaluated 
by LV end- diastolic (ED) and end- systolic (ES) dimensions; and a decrease 
of LV ejection fraction and fractional shortening (FS) compared to their litter-
mates. At end- point, AC8TM exhibited an increased heart weight/tibia length 
ratio (1.02±0.13 vs 0.77±0.11, p<0.01). Histological examination revealed an 
increase in interstitial ¿ brosis and higher cardiomyocytes cross- sectional area 
(m2: 204.65±48.55 vs. 100.86±5.05, p<0.01). Echocardiography in aging 
mice showed a decrease in systolic function (FS%: 49.47±5.43 vs 24.56±4.96, 
p<0.05), an increase in in LVED (cm: 0.49±0.04 vs 0.37±0.03 p<0.01) and 
LVES diameters (cm: 0.37±0.05 vs 0.19±0.03, p<0.01). Invasive hemodynamic 
measurements showed an increase in heart rate (HR, b/min: 629±68 vs 487±86, 
p< 0.01) with enhanced systolic (dP/dt max: 8869±4421 vs 5293±1107, p<0.01) 
and diastolic (- dP/dt min: 7476±3800 vs 4994±1208, p<0.01) ventricular func-
tion. Furthermore, during hemodynamic recording, arrhythmias were recorded 
in 7 out of 12 AC8TM, vs none in WT; ECG analysis is underway. Altogether, 
this study lead us to conclude that increasing cAMP/PKA signaling, here by the 
over- expression of adenylyl cyclase, causes a progressive alteration of cardiac 
function leading to dilated and hyperkinetic cardiopathy.
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Acute myocarditis (AM) diagnosis is a challenge based on the associa-
tion of clinical and para- clinical criteria. This pathology is thought to favour 
the evolution towards dilated cardiomyopathy and the occurrence of severe 
arrhythmias. Three months after the acute episode, re- evaluation including 
cardiac MRI could help to identify patients at risk for unfavourable evolution. 
The use of MRI has rarely been investigated in AM prognosis strati¿ cation.
Method and results: we report a prospective series of 43 consecu-
tive patients hospitalized for AM: 36 men and 7 women, 32 years old on 
average, without sign of heart failure. All patients presented with tropo-
nine I elevation. Echocardiography showed moderate global left ventri-
cular dysfunction in 6 cases and segmental wall motion abnormalities in 
22. MRI performed early after admission showed subepicardial delayed- 
enhancement (DE) areas in 39 cases mainly located in lateral segments. 
Three months after the acute episode, no patient was symptomatic. 
Echocardiography, Holter monitoring and biological check- up were normal. 
MRI showed the persistence of DE in 23 cases without wall motion abnor-
mality in the affected segments. The presence of these latter abnormalities 
led to effect an annually clinical examination with an ECG. One patient 
was lost at further follow- up. Among the other 22 patients, only one patient 
dysplayed heart failure revealing dilated cardiomyopathy with ventricular 
arrhythmias at 3–year mean follow- up.
Conclusions: at the time of admission, the absence of early perfusion 
defect at cardiac MRI after gadolinium injection and the subepicardial loca-
lization of the DE constitute reliable criteria in favour of AM diagnosis, 
allowing to rule out an acute coronary syndrome. During the follow- up the 
persistence of a DE does not allow any prognosis strati¿ cation. In our series 
after a mean 3- year follow- up, it is not associated with any clinical and para- 
clinical disorder except in one case.
